Ultrasmall Copper (I) Sulfide Nanoparticles Prevent Hepatitis B Virus Infection

Angew Chem Int Ed Engl. 2021 Jun 1;60(23):13073-13080. doi: 10.1002/anie.202103717. Epub 2021 May 6.

Abstract

Hepatitis B virus (HBV) poses a severe threat to public health and social development. Here, we synthesized 4±0.5 nm copper (I) sulfide (Cu2 S) nanoparticles (NPs) with 46 mdeg chiroptical property at 530 nm to selectively cleavage HBV core antigen (HBcAg) and effectively blocked HBV assembly and prevented HBV infection both in vitro and in vivo under light at 808 nm. Experimental analysis showed that the chiral Cu2 S NPs specific bound with the functional domain from phenylalanine23 (F23 ) to leucine30 (L30 ) from HBcAg primary sequence and the cutting site was between amino acid residues F24 and proline25 (P25 ). Under excitation at 808 nm, the intracellular HBcAg concentration was reduced by 95 %, and in HBV transgenic mice, the levels of HBV surface antigen (HBsAg) and HBV DNA were decreased by 93 % and 86 %, respectively. Together, these results reveal the potential nanomedicine for HBV control and provide fresh tools for viral infection.

Keywords: Cu2S; chirality; nanoparticles; photoinduced treatment; ultrasmall scale.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacology*
  • Copper / chemistry
  • Copper / pharmacology*
  • Hepatitis B / drug therapy*
  • Hepatitis B / metabolism
  • Hepatitis B Surface Antigens / metabolism
  • Hepatitis B virus / drug effects*
  • Mice
  • Mice, Transgenic
  • Microbial Sensitivity Tests
  • Nanoparticles / chemistry*

Substances

  • Antiviral Agents
  • Hepatitis B Surface Antigens
  • Copper
  • cupric oxide